DE3663108D1 - Process for isolating and purifying the hepatitis b surface antigen - Google Patents

Process for isolating and purifying the hepatitis b surface antigen

Info

Publication number
DE3663108D1
DE3663108D1 DE8686870069T DE3663108T DE3663108D1 DE 3663108 D1 DE3663108 D1 DE 3663108D1 DE 8686870069 T DE8686870069 T DE 8686870069T DE 3663108 T DE3663108 T DE 3663108T DE 3663108 D1 DE3663108 D1 DE 3663108D1
Authority
DE
Germany
Prior art keywords
hepatitis
purifying
isolating
surface antigen
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8686870069T
Other languages
German (de)
English (en)
Inventor
Wijnendaele Frans Van
Guy Simonet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline RIT
Original Assignee
SmithKline RIT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline RIT filed Critical SmithKline RIT
Application granted granted Critical
Publication of DE3663108D1 publication Critical patent/DE3663108D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Magnetic Heads (AREA)
  • Adornments (AREA)
  • Insulated Conductors (AREA)
DE8686870069T 1985-05-30 1986-05-21 Process for isolating and purifying the hepatitis b surface antigen Expired DE3663108D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/739,415 US4649192A (en) 1985-05-30 1985-05-30 Method for the isolation and purification of hepatitis B surface antigen using polysorbate

Publications (1)

Publication Number Publication Date
DE3663108D1 true DE3663108D1 (en) 1989-06-08

Family

ID=24972199

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686870069T Expired DE3663108D1 (en) 1985-05-30 1986-05-21 Process for isolating and purifying the hepatitis b surface antigen

Country Status (12)

Country Link
US (1) US4649192A (cg-RX-API-DMAC7.html)
EP (1) EP0204680B1 (cg-RX-API-DMAC7.html)
JP (1) JPS61280438A (cg-RX-API-DMAC7.html)
AT (1) ATE42679T1 (cg-RX-API-DMAC7.html)
AU (1) AU589331B2 (cg-RX-API-DMAC7.html)
CA (1) CA1259922A (cg-RX-API-DMAC7.html)
DE (1) DE3663108D1 (cg-RX-API-DMAC7.html)
DK (1) DK247586A (cg-RX-API-DMAC7.html)
ES (1) ES8706444A1 (cg-RX-API-DMAC7.html)
GR (1) GR861357B (cg-RX-API-DMAC7.html)
PT (1) PT82644B (cg-RX-API-DMAC7.html)
ZA (1) ZA863935B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
JPS63501121A (ja) * 1985-08-15 1988-04-28 アムジエン 酵母細胞からｂ型肝炎表面抗原を抽出するための細胞溶解法および緩衝液
US4742158A (en) * 1986-04-25 1988-05-03 Merck & Co., Inc. Purification of hepatitis pre-S antigens by polymerized serum albumin affinity binding
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
RU1389060C (ru) * 1986-08-13 1993-06-30 Институт иммунологии Способ получени рекомбинатной вакцины к гепатиту В
US4683293A (en) * 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
ATE91304T1 (de) * 1987-02-27 1993-07-15 Merck & Co Inc Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.
IL86833A0 (en) * 1987-06-22 1988-11-30 Medico Labs Peptide containing immunogenic particles
US4883865A (en) * 1987-09-30 1989-11-28 Merck & Co. Inc. Recovery of pres2+s antigen
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
US5030720A (en) * 1988-09-01 1991-07-09 Merck & Co., Inc. Pres2+S hepatitis B vaccine derived from plasma
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
EP0533492A3 (en) * 1991-09-18 1994-08-10 Amgen Inc A hepatitis b vaccine formulation incorporating a bile acid salt
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
US20040057969A1 (en) * 2002-09-20 2004-03-25 Smith Mark L Compositions containing stabilized hepatitis antigen and methods of their use
CA2617362A1 (en) * 2005-08-02 2007-02-08 Novartis Vaccines And Diagnostics S.R.L. Reducing interference between oil-containing adjuvants and surfactant-containing antigens
EP2024520B1 (en) 2006-05-11 2014-03-05 Becton, Dickinson and Company Method of protein extraction from cells
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2303562A1 (fr) * 1975-03-14 1976-10-08 Community Blood Council Greate Nouvelle preparation d'antigene utilisable comme vaccin
US4113712A (en) * 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
US4102996A (en) * 1977-04-20 1978-07-25 Merck & Co., Inc. Method of preparing hepatitis B core antigen
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4234564A (en) * 1977-12-19 1980-11-18 Merck & Co., Inc. Hepatitis B core antigen composition
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
JPH0625069B2 (ja) * 1981-01-29 1994-04-06 ブリティッシュ・テクノロジー・グループ・リミテッド Ｂ型肝炎ワクチン製造方法
GR76274B (cg-RX-API-DMAC7.html) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
EP0135435A3 (en) * 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenic hbsag derived from transformed yeast
JPS60197629A (ja) * 1984-03-16 1985-10-07 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法

Also Published As

Publication number Publication date
JPS61280438A (ja) 1986-12-11
EP0204680B1 (fr) 1989-05-03
DK247586A (da) 1986-12-01
ES555442A0 (es) 1987-07-01
AU5790686A (en) 1986-12-04
ZA863935B (en) 1987-03-25
US4649192A (en) 1987-03-10
PT82644A (en) 1986-06-01
GR861357B (en) 1986-09-25
JPH0450294B2 (cg-RX-API-DMAC7.html) 1992-08-13
ES8706444A1 (es) 1987-07-01
EP0204680A2 (fr) 1986-12-10
CA1259922A (en) 1989-09-26
AU589331B2 (en) 1989-10-05
EP0204680A3 (en) 1987-01-14
PT82644B (pt) 1988-03-03
DK247586D0 (da) 1986-05-27
ATE42679T1 (de) 1989-05-15

Similar Documents

Publication Publication Date Title
DE3663108D1 (en) Process for isolating and purifying the hepatitis b surface antigen
MY102936A (en) Process for the extraction and purification of proteins from culture media producing them.
AU1093088A (en) Hepatitis b virus surface antigens and hybrid antigens containing them
AU7466887A (en) Method for modifying the surface of finely divided silica
DE3665916D1 (en) Support for the elastic suspension of the engine in a motor-car with respect to the chassis of the same
EP0027262A3 (en) Purification of interferon
PT82345B (en) Process for the reduction of nitrogen oxides
HUP9801223A3 (en) Method for enhancing the antibody response to specific antigens with interleukin-10
EP0631633A4 (en) SELECTION BY REACTION FOR THE EXPRESSION AND CONCENTRATION OF CATALYTIC FRACTIONS.
AU6663990A (en) Chimeric mouse-human antibodies with specificity to hiv antigens
DE3665074D1 (en) Process for reducing unburned combustion particles, and agent for carrying out the process
AU1493995A (en) Monoclonal antibody
AU3330184A (en) Immune interferon and method for its purification
GB2064322B (en) Process for purifying particles of biological origin particularly the surface antigen of the virus of hepatitis b (aghbs)
AU1516988A (en) Method of preparing highly purified alpha-1-proteinase inhibitor
GB2143613B (en) Hydraulic buffer for elevators with air flow to remove contaminants
KR970061272A (ko) B형 간염 표면 항원의 정제방법
AU653182B2 (en) Process for selective removal of salivary alpha-amylase and assay for pancreatic alpha-amylase
AU7545587A (en) Process for affinity chromatographic separation of enzymes from aqueous solutions with the aid of solid carriers and specific ligands bound thereto
AU606574B2 (en) Hepatitis b surface antigen formed by recombinant dna techniques, vaccines diagnostics, cell lines and methods of forming same
JPS6441140A (en) Phosphor affixing method for glass bulb
AU3596489A (en) Method for suppressing process dust emissions
AU530850B3 (en) Method for purifying or concentrating antigens
SE8904092L (en) Fillet arrangement for holding glass panes in window - is made of composite material with low through passage coefficient and density

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DER PATENTINHABER LAUTET RICHTIG: SMITHKLINE BIOLOGICALS S.A., GENVAL RIXENSART, BE

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee